Author Archive: Jim Greenwood

Jim Greenwood

Jim joined BIO as President & CEO in 2005 after representing the eighth district of Pennsylvania in the U.S. House of Representatives for six terms.  He had worked with BIO while in Congress on stem cell research and other health issues, and has since learned so much about the many applications of the science in food and agriculture and in industrial and environmental biotechnology.

Due to its revolutionary research and development in issues ranging from feeding the world by increasing crop yields to healing the world with new medicines to providing cleaner sources of energy, Jim is a passionate champion for biotechnology. When visiting member companies, he is inspired by executives and scientists who are united in their mission to help patients, farmers and other consumers lead a better life.

Prior to Congress, Jim served in the Pennsylvania House of Representatives and Pennsylvania Senate for six years each.  He and his wife Tina live in historic Washington Crossing, Pennsylvania (where he has participated in the re-enactment of George Washington crossing the Delaware River on Christmas Day in 1776). He enjoys fishing, birding and scuba diving.

You can find him on Facebook at https://www.facebook.com/jamescgreenwood.

Latest Posts

BIO Launches New Website Holding Insurers Accountable: Un-surance.com

medical_research

BIO is undertaking an aggressive effort to promote the value of biopharmaceutical innovations and ensure that all patients have access to the drugs they need. A vital component of this campaign is holding insurers and their allies accountable for standing in the way of that access. For months, we’ve blown the whistle on their discriminatory practices, high cost-sharing and cost-shifting, and their blatant falsehoods on what’s driving their premium increases, and today, we’re introducing a Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

Latest One-Sided CNBC Interview Repeats Falsehoods, Offers Misleading Statistics

new-bio-logo

I was disappointed by CNBC’s one-sided reporting in an article that repeated numerous falsehoods and misleading statistics that have been previously debunked, apparently based on a single interview with Dr. Kenneth Davis, the President and CEO of Mount Sinai Medical. Unfortunately, this is nothing new. The insurance industry and its allies continue to use the biopharmaceutical industry as a scapegoat for their ever-increasing insurance premiums, deductibles, and co-pays. It’s time to set the record straight. Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Principles Put Patients First

Greenwood_Jim_BTN

Patient advocacy organizations play an indispensable role in the biopharmaceutical development process: They help scientists and researchers better understand what it’s like to live with the diseases they’re trying to cure. That’s why BIO and our member companies are deeply committed to meaningful partnerships with patient advocacy organizations as we work to discover new medications to help patients live longer, healthier, more fulfilling lives. Today, there are more than 250 biotechnology health care medications and Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Despite Latest Report, ICER Still Limits Patient Input and Maintains Strong Ties To Insurers

Greenwood_Jim_BTN

After months of criticism, including some from BIO, the Institute for Clinical and Economic Review (ICER) released a document that tries to address many of the legitimate and persistent concerns that have been raised. We appreciate that ICER is taking such criticism more seriously, and recently opened up its methodology to more public comment.  However, after reviewing the document, it remains clear to us that ICER still doesn’t quite get why so many organizations, including Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , ,

The Washington Post Unfairly Attacks The Orphan Drug Act

Greenwood_Jim_BTN

The Orphan Drug Act has been a tremendous success and addressed a market failure by providing incentives to bring new treatments to those suffering with rare diseases. That’s why I was deeply troubled by Friday’s unfair article in The Washington Post targeting the Orphan Drug Act through selective and unsubstantiated attacks that seem designed to undermine this bipartisan and hugely successful regime that has helped so many patients with rare diseases live longer and healthier Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,